Today is the Denosumab PDUFA date for treatment (rather than prevention) of bone mets; the phase-3 trial in bone-met prevention is due to report data any day.
In the best case for EXEL, XL184 will still be several years behind Denosumab, assuming both make it to market in the bone-met-prevention indication.
Market Data 
Markets 
AI
